We would like to request the following correction to our publication, we appreciate your help.

In the results section of the abstract:
Currently reads:
Commercial and primary culture AMSCs and commercial BMSCs demonstrated no statistically significant difference in their migration towards glioma conditioned media in vitro. There was statistically significant difference in the proliferation rate of both commercial AMSCs and BMSCs as compared to primary culture AMSCs, suggesting primary cultures have a slower growth rate than commercially available cell lines.

Change requested:
Commercial and primary culture AMSCs and commercial BMSCs demonstrated no statistically significant difference in their migration towards glioma conditioned media in vitro. There was statistically significant difference in the proliferation rate of commercial AMSCs as compared to primary culture AMSCs, suggesting primary cultures have a slower growth rate than commercially available cell lines.

In the discussion section:
Second paragraph currently reads:

AMSC and BMSC cell proliferation rates

There were statistically significant differences between commercial BMSCs and commercial and primary culture AMSC lines. These differences were most notable between the commercial BMSC and primary culture AMSC lines, suggesting that primary cultures may not grow as robustly as their commercially obtained counterparts. Further research comparing primary culture BMSCs to primary culture AMSCs may be required prior to clinical usage of MSCs. Our observational data has indicated that while BMSCs and AMSCs proliferate at similar rates in the 24-well growth assay, BMSC demonstrate slower growth characteristics when grown in larger culture flasks and at lower seeding densities (not shown); this finding has been documented elsewhere in the literature [35]. The proliferative capacity of MSCs may be important not only in maximizing clinical applications, but also in minimizing the risk of oncogenic or malignant transformation, which has been linked to the length of ex vivo culture in some studies [33], [40]. This may influence the choice of an MSC source when transitioning to clinical applications, as large-scale expansion of individual patient MSCs will be necessary.

Change requested:
There were statistically significant differences between commercial and primary cultured AMSC lines. These differences suggest that primary cultures may not grow as robustly as their commercially obtained counterparts. Further research comparing primary culture BMSCs to primary culture AMSCs may be required prior to clinical usage of MSCs. Our observational data has indicated that while BMSCs and AMSCs proliferate at similar rates in the 24-well growth assay, BMSC demonstrate slower growth characteristics when grown in larger culture flasks and at lower seeding densities (not shown); this finding has been documented elsewhere in the literature [35]. The proliferative capacity of MSCs may be important not only in maximizing clinical applications, but also in minimizing the risk of oncogenic or malignant transformation, which has been linked to the length of ex vivo culture in some studies[33,40]. This may influence the choice of an MSC source when transitioning to clinical applications, as large-scale expansion of individual patient MSCs will be necessary.